Kevin DAmour - Mar 11, 2022 Form 4/A - Amendment Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Role: Chief Scientific Officer
Signature: /s/ Kevin D'Amour
Stock symbol: ERNA
Transactions as of: Mar 11, 2022
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 3/17/2022, 09:00 PM
Date Of Original Report: Mar 15, 2022
Previous filing: Jun 30, 2021
Next filing: Jun 29, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ERNA	Stock Option (Right to buy)	Award	$0	+138K		$0.00	138K	Mar 11, 2022	Common Stock	138K	$1.93	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options vest and become exercisable in 36 substantially equal monthly installments from the grant date.

Remarks:

This Form 4/A amends and restates the original Form 4 filed by the reporting person on March 15, 2022 (the "Original Form 4"). The Original Form 4 reported incorrect vesting terms.